GSK2269557

GSK2269557 (订货以CAS编码或英文名称为准)

PI3Kδ抑制剂,Nemiralisib, also known as GSK-2269557, is a potent and selective PI3Kδ inhibitor. GSK-2269557 is is currently in clinical trials for the treatment of respiratory diseases such as asthma and COPD.
MedBio提供的所有产品仅用于科研等非医疗用途,非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。如您需要产品COA等资料,可至下方“质量控制”中下载
编号:MED18210
分子式:C27H30CLN5O
CAS号:1254036-77-5
分子量:476.01
申请试用
货号 品牌 规格 纯度/含量 标准价 优惠价 库存货期 数量 购买
MED18210-10mg MedBio 10mg ≥98% ¥5305.00 登录后可见
MED18210-25mg MedBio 25mg ≥98% ¥11615.00 登录后可见
MED18210-5mg MedBio 5mg ≥98% ¥2980.00 登录后可见
中文名称: 2-(6-(1H-Indol-4-yl)-1H-indazol-4-yl)-5-((4-isopropylpiperazin-1-yl)methyl)oxazole hydrochloride
中文别名: 6-(1H-吲哚-4-基)-4-[5-[[4-(1-甲基乙基)-1-哌嗪基]甲基]-2-恶唑基]-1H-吲唑盐酸盐
英文名称: GSK2269557
英文别名: 2-(6-(1H-Indol-4-yl)-1H-indazol-4-yl)-5-((4-isopropylpiperazin-1-yl)methyl)oxazole hydrochloride;GSK-2269557
CAS号: 1254036-77-5
分子式: C27H30CLN5O
分子量: 476.01
PI3Kδ抑制剂,Nemiralisib, also known as GSK-2269557, is a potent and selective PI3Kδ inhibitor. GSK-2269557 is is currently in clinical trials for the treatment of respiratory diseases such as asthma and COPD.
搜索质检报告(COA)
相关产品